Apellis Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	22.39	-197.88	-528.63	-652.17	-746.35
Depreciation & Amortization	1.56	1.8	1.78	1.55	1.49
Stock-Based Compensation	-	114.13	105.95	91.09	70.67
Other Adjustments	2.5	12.44	26.41	61.55	204.59
Change in Receivables	-101.28	-58.48	-198.72	2.38	-10.1
Changes in Inventories	-15.27	-10.76	-60.65	-69.4	-16.32
Changes in Accounts Payable	18.22	1.09	0.17	18.69	10.49
Changes in Accrued Expenses	25.39	18.15	34.95	-6.31	-10.39
Changes in Other Operating Activities	-12.18	31.64	23.99	38.88	-67.2
Operating Cash Flow	45.33	-87.87	-594.74	-513.75	-563.13
Capital Expenditures	-0.31	-0.4	-0.77	-1.52	-1.1
Sale of Property, Plant & Equipment	-	-	0.1	-	-
Purchases of Investments	-	-	-	-331.86	-171.28
Proceeds from Sale of Investments	-	-	-	393.28	420
Investing Cash Flow	-0.31	-0.4	-0.67	59.89	247.62
Short-Term Debt Issued	-	365.45	-	-	-
Net Short-Term Debt Issued (Repaid)	-	365.45	-	-	-
Issuance of Common Stock	8.9	18.83	461.04	405.84	398.02
Repurchase of Common Stock	-0.01	-0.06	-11.04	-5.68	-1.79
Net Common Stock Issued (Repurchased)	8.88	18.77	450	400.16	396.24
Other Financing Activities	-	-234.98	-55.5	-34.5	-4
Financing Cash Flow	8.88	149.24	394.5	365.66	392.24
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1.25	-0.66	0.14	-0.49	-2.02
Net Cash Flow	55.15	60.31	-200.78	-88.68	74.71
Free Cash Flow	45.01	-88.27	-595.51	-515.27	-564.23
FCF Margin	4.48%	-11.30%	-150.16%	-683.18%	-847.66%
Free Cash Flow Per Share	0.35	-0.71	-5.02	-4.86	-6.68
Levered Free Cash Flow	39.79	209.1	-529.15	-670.28	-829.38
Unlevered Free Cash Flow	68.87	-124.43	-519.74	-613.33	-619.56

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.